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Abstract 
The inhalation route is widely studied for many drug applications focusing on either local or systemic 
distributions. One matter of concern is the solubilization of hydrophobic drugs. 
We have studied the feasibility of using different cyclodextrins (CDs) to elaborate pharmaceutical formulations 
for the inhalation route and tested the short-term toxicity of such formulations administered by inhalation to 
C57BL/6 mice. 
We have shown that HP-β-CD, γ-CD, as well as RAMEB aqueous solutions can undergo aerosolization and that 
the resulting droplet-size ranges are compatible with pulmonary deposition. In vivo, we have demonstrated that 
short-term exposure to inhaled HP-β-CD, γ-CD and RAMEB solutions are non-toxic after assessing 
bronchoalveolar lavage (BAL), lung and kidney histology, bronchial responsiveness to methacholine and blood 
urea. The only change noted is a slight increase in lymphocyte count in the BAL after HP-β-CD and γ-CD 
inhalation. 
We conclude that CDs are useful in significantly enhancing the solubility of apolar drugs with a view to 
inhalation therapy although an increase in lymphocyte counts in the BAL after CDs inhalations needs further 
investigations. 
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1. INTRODUCTION 
The respiratory tract has become an increasingly attractive route of application for a wide range of active 
substances with either topic or systemic pharmacological activity and the trend towards a systemic application of 
drug compounds via the lung is rapidly increasing [1]. New drug delivery systems, such as microparticles, 
nanoparticles or liposomes, may enhance the systemic bioavailability of substances applied to the lung by 
offering relative protection against degrading factors, as well as by exhibiting controlled release properties [2]. 
Recently, pulmonary delivery has emerged as a possibility for non-invasive delivery of protein and 
macromolecular drugs. A major obstacle to the widespread use of pulmonary drug delivery is the relative 
impermeability of the lung to many of these peptide and macromolecular drugs when they are administered 
without an absorption enhancer. Cyclodextrins (CDs) have been reported as potential absorption enhancer in 
pulmonary protein delivery [3], 
Cyclodextrins are cyclic oligosaccharides consisting of covalently linked glucopyranose rings. α-, β-, and γ-CDs 
are naturally occurring CDs combining six, seven or eight glucopyranose units. The CDs and their hydrophilic 
derivatives are used in pharmaceutical formulations to enhance solubility, dissolution rate, stability and 
bioavailability. The fact that they enhance solubility may be explained by the formation of water-soluble 
inclusion complexes in which the hollow, truncated, cone-like CD structure encapsulates hydrophobic drug 
molecules in the apolar interior. In contrast, the outer, hydrophilic region of the CD induces solubilization 
through interaction with water molecules [4]. Little has yet been published concerning the pulmonary 
applications of cyclodextrins [5-8]. It was found that hydrophilic cyclodextrin derivatives could be used in liquid 
formulation to be administered by inhalation thus increasing drugs solubility, but very little data was given as to 
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the potential toxicity of CD formulations on the lung parenchyma and bronchial tree. It is generally accepted that 
aerosol particles of 0.5-5 µm are required for deposition in the alveolar region of the lung. The primary factors 
influencing aerosol particle size and, ultimately, the site of aerosol deposition include the design of the inhalation 
device, as well as the physico-chemical properties of the formulation [9]. Both the viscosity of the solution and 
surface tension characteristics play an important part in the formation of the droplets during nebuliza-tion 
[10,11]. To date, there are no data available regarding the characterization of aerosols obtained with such 
cyclodextrins solutions. 
To determine the potential advantage of using CD-drugs complexes for pulmonary administration, several CDs 
have been considered in this work for their ability to form respirable aerosol droplets from liquid formulation 
containing different concentrations of CD. Among the hydrophilic CDs, 2-hydroxypropyl-β-cyclodextrin (HP-β-
CD), methylated-β-cyclodextrin (RAMEB) and gamma-cyclodextrin (γ-CD) appear to be especially useful —
considering their safety profiles in humans [12]. In this work, we also address the potential lung toxicity of 
cyclodextrins inhalation in vivo, by administering inhalations of different CDs at various dosages to mice. In this 
way, bronchial responsiveness, airway inflammation and histological changes, blood urea and renal histology 
can be assessed. 
2. MATERIALS AND METHODS 
2.1. Materials 
HP-β-CD (degree of substitution = 0.64) was a gift from Roquette (France). Randomly methylated-β-CD 
(RAMEB) and γ-CD were generously given by Wacker Chemie (Germany). Apyrogenic phosphate-buffered 
saline (PBS) was purchased from Bio-Wit-taker (Verviers, Belgium). Methacholine was from Sigma-Aldrich 
(Germany). 
All other materials were of analytical grade. Sterile water for injection was used throughout this study. Sterile, 
apyrogenic and isotonic CD solutions were prepared at 20, 50 and 75 mM for HP-β-CD and RAMEB and at 20, 
50 and 100 mM for γ-CD. Cyclodextrins were tested following the Bacterial Endotoxin Test described in USP 
XXVI using Limulus Amebocyte Lysate (LAL). Osmolalities of all the solutions were measured by a Knauer 
Automatic semi-micro Osmometer and adjusted to the value of 300 mOsm/kg by the addition of an adequate 
amount of NaCl. A terminal sterilization of the solutions was performed by steam sterilization process. 
2.2. Surface tension, density, and viscosity measurements 
The surface tension measurement method consists in measuring the force that has to be exerted on a 
platine/iridium stirrup piece, which is in contact with the solution surface, to stretch the interfacial liquid film. 
Surface tension measurements were made with a Lauda TD1 tensiometer (Prolabo, Paris, France), the measuring 
range of which is 0-100 mN/m, precision 0.1 mN/m and sensitivity 0.001 mN/m. All experiments were carried 
out at 25 °C 
The density of each solution was measured by using a densitimeter Anton Paar type DMA45A Viscosity of the 
solutions, the behavior of which is Newtonian, was measured with a capillary viscosimeter following the method 
that is described in the European Pharmacopeia (Micro Ostwald viscosimeter for the determination of kinematics 
viscosity, Schott-Gerate, Germany). All experiments were carried out at 25 °C. 
2.3. Production of the aerosol 
The aerosol was produced by using an ultrasonic nebulizer SYSTAM (Système Assistance Medical, Le Ledat, 
France), the vibration frequency of which is 2.4 MHz with variable vibration intensity and ventilation levels. 
Vibration intensity was fixed in position 6 and the ventilation level was 25(v1/2) l/min. Those conditions were 
used for the characterization of the aerosols as well as for the animal exposure. 
2.4. Characterization of nebulized aerosol 
Aerosol size distribution emitted from CDs solutions was determined with a laser size analyzer Mastersizer 
(Malvern, Orsay, France). Ten milliliters of each solution was directly nebulized in the laser beam. The 
mouthpiece was held at 1 cm from the center of the laser beam. The resulting aerosol was aspirated on the 
opposite side of the beam. Environmental temperature and relative humidity were maintained constant, that is to 
say at 20 °C and 40-45%. Triplicates of each measurement were performed and compared to controls of PBS. 
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The results are expressed as the percentage of droplets comprised in the range 0.5-5.79 µm and the median 
diameter. The concentration of droplets in the air evaluated by the obscuration percentage of the laser beam was 
in the same range for each experiment (15-25%). The mass loss after nebulization was also determined after 5 
min of nebulization and was used as a measure of the nebulization rate. 
2.5. Animals and in vivo exposure 
Four groups of eight C57BL/6 mice have been tested for each investigated CDs. Three of the groups were 
exposed daily for 7 days to the inhalation of one CD concentration dispensed by the ultrasonic nebulizer, while 
the fourth received a placebo solution (PBS). The duration of inhalation was set at 30 min/day and the mice were 
exposed to aerosols in a Plexiglas exposure chamber (30 x 20 x 15 cm). The estimated amount of inhaled 
cyclodextrin was ranging from 1.3 to 4.1 µg/min/kg of body weight. 
2.6. Airway responsiveness measurement 
Twenty-four hours after the final exposure, bronchial hyperresponsiveness was determined by measuring the 
Penh using a barometric plethysmograph as proposed by Hamelmann et al. [13]. The Penh was measured at 
baseline and 5 min after the inhalation of increasing doses (25, 50, 75 and 100 mM) of methacholine (Mch). 
2.7. Bronchoalveolar lavage (BAL) and histology 
Immediately after the assessment of airway responsiveness, mice were sacrificed and 1 ml of PBS free of ionised 
calcium and magnesium but supplemented with 0.05 mM sodium EDTA was instilled four times via a tracheal 
cannula and recovered by gentle manual aspiration. The recovered bronchoalveolar lavage fluid (BALF) was 
centrifuged (1800 rpm for 10 min at 4 °C). The supernatant was processed for protein assessments whereas the 
cell pellet was washed twice and finally resuspended in 1 ml of PBS. A total cell count was performed in a 
Thoma chamber and the differential cell counts on at least 400 cells were performed on cytocentrifuged 
preparations (Cytospin 2; Cytospin, Shandon td., Runcorn, Cheshire, UK) using standard morphologic criteria 
after staining with Diff-Quick (Dade, Germany). After BAL, the thorax was opened and the left main bronchus 
was clamped. The left lung was excised and frozen immediately in liquid N2 for protein chemistry and mRNA 
extraction while the right lung was processed for histology. As previously described [14], the right lung was 
infused with 4% paraformaldehyde and embedded in paraffin. Sections of 4-µm thickness from all lobes were 
stained with haematoxylin and eosin. The extent of peribronchial infiltrates was estimated by an inflammation 
score. Slides were coded and the peribronchial inflammation was graded in a blinded fashion using a 
reproducible scoring system described elsewhere [14]. A value from 0 to 3 per criteria was adjudged to each 
tissue section scored. A value of 0 was adjudged when no inflammation was detectable, a value of 1 for 
occasional cuffing with inflammatory cells, a value of 2 when most bronchi were surrounded by a thin layer (1 to 
5 cells) of inflammatory cells and a value of 3 when most bronchi were surrounded by a thick layer (>5 cells) of 
inflammatory cells. As 5-7 randomly selected tissue sections per mouse were scored, inflammation scores could 
be expressed as a mean value per animal and could be compared between groups. The left lung was snap frozen 
in liquid nitrogen and crushed using a Mikro-Dismembrator S (Braun Biotech International, Melsungen, 
Germany). Kidneys were excised and paraffin embedded, sections of 4 µm were stained by haematoxylin and 
eosin. Blood was sampled by cardiac puncture and serum was stored at -80°C until analyses were performed. 
Serum urea was measured using a spectrophotometer measuring the absorbance of the samples at 520 nM after 
adding an aqueous solution of diacetylmonoxime, thiosemicarbazide, sulfuric acid, phosphoric acid as previously 
described [15]. 
All in vivo manipulations were approved by the local Veterinarian Ethics Committee. 
3. RESULTS 
3.1. Determination of the physico-chemical characteristics of the solution 
The measured density values in the CDs concentration range tested were close to that of water while an increase 
in the viscosity of the solutions was related to the increase of in CDs concentration. Table 1 shows the density, 
the viscosity and the surface tension data obtained for water and solutions of HP-β-CD, RAMEB and γ-CD at 
five different concentration levels. At the same concentration, γ-CD solutions displayed lower viscosity than the 
β-CD derivatives. It confirms the results reported by Müller et al. [16] and Thompson [17] which showed that 
the substitution of native CDs reduces the surface activity of the molecule and that the methylated compounds 
show the greatest lowering. 
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The influence of the CDs concentration on the surface tension was negligible in the range of the CDs 
concentrations studied in the present work. 
3.2. Influence of CDs concentration on droplets size 
The CDs solutions density close to 1 g/cm3 and the spherical shape of the droplets measured meant that the 
percentage of droplets in the range of 0.5-5.79 µm could be assimilate to respirable fraction (RF) and median 
diameter to mass median aerodynamic diameter (MMAD) [18,19]. Table 2 shows the results for the percentage 
of droplets comprised in the range of 0.5-5.79 µm, the median diameter and the geometric standard deviation 
(GSD). A comparison of the MMAD, the GSD and the percentage of droplets comprised in the range of 0.5-5.79 
µm of all the CDs solutions with the corresponding values for PBS demonstrated that the presence of CDs in the 
solution did not influence the droplet size distribution in the aerosols. A fraction of droplets comprised in the 
range of 0.5-5.79 µm close to 65% was obtained in each experiment. 
 
Table 1: Characteristics of aqueous solutions of different CDs 
 CD concentration 
(mM) 
Density Viscosity (Cst) Tension surface
(mN/m) 
Water  1 1 69.4 
HP-β-CD 20 1.004 1.07 57.4 
 50 1.016 1.20 57.1 
 75 1.028 1.43 56.9 
 100 1.031 1.52 55.1 
RAMEB 20 1.004 1.09 47.2 
 50 1.015 1.21 46.5 
 75 1.026 1.46 46.5 
 100 1.033 1.64 46.9 
γ-CD 20 1.006 1.11 66.5 
 50 1.020 1.18 66.5 
 75 1.032 1.30 68.1 
 100 1.044 1.45 67.5 
 150 1.068 1.82 66.9 
 
Table 2: Percentage of droplets in the range of 0.5-5.79 µm, mass median aerodynamic diameter (MMAD) and 
geometric standard deviation (GSD) 
Sol. Concentration of CD  
(mM) 
% of droplets  
(0.5-5.79 µm) 
MMAD GSD 
  Mean S.D. Mean S.D. Mean S.D.
Water 0 58.58 1.03 5.75 0.16 1.62 0.03
HPBCD 0 58.58 1.03 5.75 0.16 1.62 0.03
 20 68.11 0.95 5.55 0.56 1.40 0.03
 50 67.31 0.74 5.46 0.30 1.39 0.16
 75 62.35 0.36 5.83 0.05 1.67 0.01
 100 63.56 0.39 5.70 0.08 1.64 0.01
RAMEB 0 58.58 1.03 5.75 0.16 1.62 0.03
 20 66.38 1.00 5.31 0.07 1.30 0.03
 50 68.72 0.44 5.22 0.06 1.34 0.02
 75 70.68 2.55 5.50 0.78 1.37 0.10
 100 69.11 2.38 5.76 1.04 1.55 0.14
Gamma 0 58.58 1.03 5.75 0.16 1.62 0.03
 20 58.91 0.35 6.00 0.11 1.69 0.02
 50 64.34 3.41 5.70 0.23 1.66 0.07
 75 70.70 3.06 5.03 0.20 1.35 0.09
 100 69.39 0.58 5.14 0.08 1.48 0.02
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Fig. 1: Influence of CDs concentration on the nebulization rate. 
 
 
3.3. Influence of CDs concentration on the rate of aerosol production 
Nebulization rate decreased with the CDs concentration. This decrease was greater for RAMEB solutions 
displaying higher viscosity values. Fig. 1 shows nebulization rate as a function of the concentration of CDs for 
HP-β-CD, RAMEB and γ-CD. Solutions with a viscosity higher than 1.45 led to nebulization rates lower than 
0.2 g/min resulting in aerosol's duration which are not compatible with human administration. The maximal CDs 
concentrations for in vivo experiments were then fixed at 75 mM for both HP-β-CD and RAMEB and to 100 
mM for γ-CD. 
3.4. In vivo evaluation 
3.4.1. BAL cellularity 
When compared to PBS exposed control mice there, was a slight decrease in total number of cells recovered by 
BAL in the HP-β-CD-treated group only at the dose of 75 mM (p<0.05) (Table 3). The number of BAL epithelial 
cells was similar to controls in all CDs and concentrations tested, indicating that the inhalation of the 
formulations did not induce any significant epithelial shedding. As regards inflammatory cells, the only 
significant difference is a slight increase in the number of lymphocytes compared to controls in mice exposed to 
20 mM HP-β-CD and at all doses tested for γ-CD (20, 50, 100 mM) (Table 3). 
3.4.2. Histology 
There were no significant changes in lung histology after a 1-week daily inhalation of HP-β-CD, γ-CD and 
RAMEB solutions. In particular, the integrity of the epithelium was verified by observation and the presence of 
inflammation was assessed by calculating an inflammation score which showed no difference between the CD-
exposed mice and controls. 
3.4.3. Bronchial responsiveness 
Bronchial responsiveness was assessed in each mice by measurement of the Penh for 5 min after inhaling 
different concentrations of MCh (20, 50 and 100 mM). HP-β-CD, HP-γ-CD, and RAMEB exposure for 7 days 
did not significantly influence bronchial responsiveness when considering the values of the Penh or some 
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previously published indices proposed as indicators of bronchial responsiveness (PC200 which is the MCh 
concentration at which the lung resistance display a 200% increase). 
3.4.4. Kidney histology 
Based on morphological criteria, no difference was noted in kidney histology studied in standard light 
microscopy between all different groups exposed to CDs inhalation and controls. 
3.4.5. Blood urea levels 
In every experimental group, there were no significant differences in blood urea levels between the CD-exposed 
and control mice. 
Table 3: BAL cell counts after placebo (PBS) or CDs exposure (n = 8 per experimental condition) 
 HP-β-CD 
 PBS 20 mM 50 mM 75 mM 
Epithelial cells (103/ml) 4.1 ±2.5 3.9 ± 1.6 4.2 ± 1 1.6 ± 0.9 
Eosinophils (103/ml) 0 ± 0 0.1 ± 0.07 0.02 ± 0.02 0 ± 0 
Neutrophils (103/ml) 0.07 ± 0.03 0.2 ± 0.07 0.02 ± 0.02 0.03 ± 0.02 
Lymphocytes (103 /ml) 0.2 ± 0.1 0.7 ± 0.1* 0.4 ± 0.3 0.2 ± 0.1 
Macrophages (103 /ml) 30.9 ± 6.5 44.4 ± 5.4 44.5 ± 6.3 12 ± 5.5 
Total cells (103/ml) 41.5 ± 4.5 49.4 ± 6.2 49.1 ± 7.2 13.8 ± 6.5* 
 
 γ-CD 
 PBS 20 mM 50 mM 100 mM 
Epithelial cells (103/ml) 2.8 ± 0.7 2 ± 0.5 3.3 ± 1 2.6 ± 0.7 
Eosinophils (103 /ml) 0 ± 0 0.002 ± 0.002 0 ± 0 0 ± 0 
Neutrophils (103/ml) 0 ± 0 0.02 ± 0.02 0.3 ± 0.2 0.2 ± 0.1 
Lymphocytes (103 /ml) 0.1 ± 0.09 1.9 ± 0.4* 2.1 ± 0.8* 2.3 ± 1* 
Macrophages (103/ml) 25.5 ±7.3 25.4 ± 4.4 33.7 ± 5.9 45.1 ± 6.7 
Total cells (103/ml) 28.4 ± 7.4 29.4 ± 4.8 39.3 ± 6.6 50.2 ± 7.6 
 
 RAMEB 
 PBS 20 mM 50 mM 75 mM 
Epithelial cells (103/ml) 6.6 ± 1.8 2 ± 1.3 2.6 ±0.8 6.1 ± 1.4 
Eosinophils (103 /ml) 1.1 ±0.8 0.2 ± 0.2 0.6 ±0.5 0 ± 0 
Neutrophils (103/ml) 0.1 ±0.1 0±0 0.1 ±0.1 0.1 ± 0.1 
Lymphocytes (103 /ml) 1.1 ±0.8 0±0 0.1 ±0.1 0.1 ± 0.1 
Macrophages (103/ml) 34.4 ± 7.5 18.4 ± 4.9 16.1 ±2.2 47.8 ± 6.4 
Total cells (103/ml) 39.8 ± 9.7 18.9 ± 3.9 20.3 ± 2.5 54.1 ±6.8 
*p<0.05 when compared to PBS exposed mice. 
 
4. DISCUSSION 
We have studied the feasibility of using CDs for the elaboration of pharmaceutical formulations intended for 
inhalation. We have described that HP-β-CD, γ-CD, as well as RAMEB aqueous solutions can undergo 
aerosolization and that the resulting droplet-size is compatible with pulmonary deposition. In vivo, we have 
demonstrated that inhaled HP-β-CD, γ-CD and RAMEB solutions are non toxic as assessed by the study of BAL, 
lung and kidney histology, bronchial responsiveness to methacholine and blood urea. The only change noted is a 
slight increase in lymphocyte count after HP-β-CD and γ-CD inhalation. 
New vehicles are required for the pulmonary administration of drugs displaying a low aqueous solubility. 
Indeed, considerable efforts are being made to find ways to make use of the pulmonary route for systemic 
therapy of drugs such as peptides which are metabolized by the digestive tract, as well as to administer drugs 
such as anti-inflammatory agents and bronchodilators. 
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Previous authors studied the pulmonary absorption of CD (β-CD, dimethyl-β-CD (DM-β-CD) and                       
2-Hydroxypropyl-β-cyclodextrin (HP-β-CD)) in rabbits through a crossover pharmacokinetics study following 
intratracheal (IT) instillation and IV injection [6] and found that serum values after IT instillations were 
considerably higher than CD absorption by other non-parenteral routes indicating that toxicity at both local and 
systemic levels was a matter of concern. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD) was investigated for 
pulmonary applications of salbutamol in a dry powder formulation, in an attempt to modify its pharmacokinetics 
properties and a rapid dissociation of the drug from the complex was observed in vivo leading the hypothesis 
that CDs can promote lung delivery of drugs [5]. CDs have been evaluated as potential drug carrier in DPI 
formulations which are the most convenient for a daily use and indicate that formulations containing CDs 
enhanced drug delivery to the lower stage of the impactor. In these studies, no data are available on the potential 
lung toxicity of CD [8]. A very recent study showed that cyclosporin A-maltosyl-α-CD complexes were useful as 
therapy for allergen-induced inflammation with an apparently low toxicity [7]. Using high doses of intravenously 
administered HP-γ-CDs (> 600 mg/kg), the occurrence of a pulmonary accumulation of macrophages 
(histiocytosis) was demonstrated [20]. In our study, the topic administration of CDs at dosages between 20 and 
100 mM in the lungs did not induce any accumulation of macrophages at all as demonstrated by BAL 
differential cell counts and histology. Interestingly, our results show an increase in lymphocyte counts in BAL 
after inhalation of HP-β-CD and HP-γ-CD. This finding could be related to interactions of CDs and some 
cholesterol/sphingolipid-rich plasma membrane microdomains present at the surface of lymphocytes and referred 
to as "lipid rafts" as demonstrated for methyl-β-CDs [21]. These lipid rafts have been demonstrated to be 
regulatory elements in a wide spectrum of cellular events such as signaling and cell adhesion [21,22]. A potential 
interaction of CDs with regulatory elements of lymphocytes trafficking could explain the increased lymphocyte 
counts in the BAL of mice exposed to HP-β-CD and γ-CD. Further in vitro studies are needed to explore more in 
depth the potential interaction with lymphocyte functions. 
In conclusion, we have demonstrated the feasibility of cyclodextrin inhalation from a technical point of view. 
The short-term safety of such inhaled formulations is accurate in terms of lung and renal integrity and function. 
An increase in lymphocyte counts in the BAL after CDs inhalations needs further investigation. 
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